Isturisa

Osilodrostat, the active ingredient in Isturisa, is a 11β‑hydroxylase inhibitor presented as an oral formulation for systemic use. It is indicated for the treatment of Cushing's disease in adults, helping to reduce excess cortisol production. The drug works by targeting adrenal enzyme activity, offering a pharmacologic option when surgery is not feasible or as adjunct therapy.

GNH USA supplies Isturisa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isturisa (osilodrostat) is used to manage hypercortisolism associated with Cushing's disease and related conditions. - Cushing's disease: lowers cortisol in adults with pituitary‑derived excess cortisol. - Cushing's syndrome (non‑pituitary): may be employed to control cortisol when surgery is not possible. - Recurrent or persistent hypercortisolism: used when cortisol remains elevated after prior therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Fatigue: feeling unusually tired or weak. - Headache: intermittent pressure or pain in the head. - Dizziness: light‑headed sensation, especially when standing. - Decreased appetite: reduced desire to eat. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Adrenal insufficiency: signs of cortisol deficiency such as severe fatigue, hypotension, or hypoglycemia. - Hypokalemia: low potassium levels causing muscle weakness or arrhythmia. - QT interval prolongation: potential cardiac rhythm disturbances. - Severe hypertension: sudden, marked increase in blood pressure. - Hepatic injury: abnormal liver function tests or jaundice. - Allergic reactions: rash, itching, swelling, or difficulty breathing.

Before starting treatment, patients should be evaluated for baseline cortisol, electrolyte, and blood pressure status. - Monitor cortisol levels: adjust dose based on biochemical response. - Assess electrolytes: watch for potassium and sodium abnormalities. - Evaluate blood pressure: treat hypertension promptly. - Review concomitant CYP11B1‑affecting drugs: avoid interactions that may alter exposure. - Counsel on pregnancy: discuss potential risks with a healthcare professional. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Osilodrostat may interact with several medication classes. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase osilodrostat exposure. - Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Concurrent glucocorticoids: risk of additive cortisol suppression. Moderate Interactions (Monitor Closely): - Antihypertensives: monitor blood pressure as cortisol reduction may alter response. - Anticoagulants (warfarin): observe INR values for potential changes. - Oral contraceptives: hormonal levels may be affected, requiring clinical review.